Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2009

01-02-2009 | Short Communication

Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma

Authors: Mehmet Emin Kalender, Alper Sevinc, Mustafa Yilmaz, Coskun Ozsarac, Celalettin Camci

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2009

Login to get access

Abstract

Malignant mesenchymal tumors consist of approximately 10% of uterine tumors. The majority of uterine sarcomas are leiomyosarcoma and endometrial stromal sarcoma (ESS). Surgery, radiotherapy, chemotherapy, and hormonal therapy are used for the treatment of ESS. Imatinib mesylate is indicated in the management of gastrointestinal stromal tumor and chronic myelogeneus leukemia. There is an interest to use imatinib mesylate in the treatment of c-kit positive ESS. We reported a case of 42-year-old female low-grade ESS progressed on chemotherapy and presented with objective response to imatinib mesylate. The treatment response was evaluated with FDG PET/CT. Complete metabolic response was detected. FDG PET, a sensitive method for tumor response evaluation on the basis of tumor metabolism changes, is useful for the evaluation of imatinib treatment in low-grade ESS.
Literature
1.
2.
Hasiakos D, Papakonstantinou K, Kondi-Paphiti A, Fotiou S (2007) Low-grade endometrial stromal sarcoma of the endocervix. Report of a case and review of the literature. Eur J Gynaecol Oncol 28:483–486PubMed
3.
De Vita Jr VT, Hellman S, Rosenberg SA (2005) Cancer: principles and practice of oncology. In: Burke Tw, Mundt AJ, Muggia FM (eds) Cancers of the uterine body. 7th edn. Chap. 32.2. Philadelphia, USA, pp 1341–1360
4.
Sevinc A, Adli M, Kalender ME, Camci C (2007) Benign causes of increased serum CA-125 concentration. Lancet Oncol 8:1054–1055PubMedCrossRef
5.
Sevinc A, Camci C, Turk HM, Buyukberber S (2003) How to interpret serum CA-125 levels in patients with serosal involvement? A clinical dilemma. Oncology 65:1–6PubMedCrossRef
6.
Amant F, Moerman P, Cadron I, Neven P, Berteloot P, Vergote I (2003) The diagnostic problem of endometrial stromal sarcoma: report on six cases. Gynecol Oncol 90:37–43PubMedCrossRef
7.
Lo KW, Yu MY, Cheung TH (2008) Low-grade endometrial stromal sarcoma with florid ıntravenous component. Gynecol Obstet Invest 66:8–11PubMedCrossRef
8.
Veroux P, Veroux M, Nicosia A, Bonanno MG, Tumminelli MG, Milone P, Petrillo G (2000) Thrombectomy of the inferior vena cava from recurrent low-grade endometrial stromal sarcoma: case report and review of the literature. J Surg Oncol 74:45–48PubMedCrossRef
9.
Ali RA, El-Hady el-SA, El-Zayat M (2008) Multilocular intrauterine cystic mass, atypical presentation of endometrial stromal sarcoma: a case report. Arch Gynecol Obstet 277:185–187PubMedCrossRef
10.
Wang KC, Liang DC, Su TH, Hung FY, Yang YC (1998) High-grade endometrial stromal sarcoma in a 10-year-old girl: case report. Changgeng Yi Xue Za Zhi 21:312–317PubMed
11.
Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS (2007) Low grade endometrial stromal sarcoma: a single center’s experience with 22 cases. Int J Gynecol Cancer (in press)
12.
Ashraf-Ganjoei T, Behtash N, Shariat M, Mosavi A (2006) Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases. World J Surg Oncol 4:50PubMedCrossRef
13.
Reich O, Regauer S (2007) Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 19:347–352PubMedCrossRef
14.
Salvatierra A, Tarrats A, Gomez C, Sastre JM, Balaña C (2006) A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. Gynecol Oncol 101:545–547PubMedCrossRef
15.
Prenen H, Deroose C, Vermaelen P, Sciot R, Debiec-Rychter M, Stroobants S, Mortelmans L, Schoffski P, Van Oosterom A (2006) Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. Anticancer Res 26:1247–1252PubMed
16.
Van Oosterom AT, Judson I, Verweij J et al (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358:1421–1423PubMedCrossRef
17.
Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A (2005) Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 25:4591–4594PubMed
18.
Sevinc A, Camci C, Yilmaz M, Buyukhatipoglu H (2007) The diagnosis of C-kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective. Onkologie 30:645–648PubMedCrossRef
19.
Zincirkeser S, Sevinc A, Kalender ME, Camci C (2007) Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging. World J Gastroenterol 13:2261–2262PubMed
Metadata
Title
Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma
Authors
Mehmet Emin Kalender
Alper Sevinc
Mustafa Yilmaz
Coskun Ozsarac
Celalettin Camci
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0786-7

Other articles of this Issue 3/2009

Cancer Chemotherapy and Pharmacology 3/2009 Go to the issue

Original Article

A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients

Original Article

Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer

Original Article

Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study

Short Communication

Pathologic complete response after palliative 3rd line chemotherapy with capecitabine alone in metastatic colorectal cancer

Letter to the Editor

Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias

Original Article

A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits